Zimbabwe has turned down a substantial American healthcare agreement valued at 367 million US dollars (£272m) over five years over the United States' insistence on sensitive information.
This move became public following a internal memorandum from December was leaked, indicating that President Emmerson Mnangagwa believed the arrangement was "skewed".
An official representative has since stated that the US was seeking biological samples for research and profit but was not willing to share the resulting advantages from future treatments.
"We must now begin the challenging and unfortunate task of winding down our health assistance in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy indicated the US had provided over $1.9bn as health assistance to Zimbabwe over the last two decades.
A medical body in Zimbabwe has urged continued dialogue to reach a deal acceptable to all parties so the nation's critical HIV programme can proceed.
Wider Background
This rejection follows a comparable situation in neighbouring Kenya, where a high court halted a similar deal with the US after concerns were raised about the safety of Kenyans' medical information.
Since resuming the presidency last year, US President Donald Trump has drastically cut foreign aid and shut down the key foreign aid agency.
The agency had overseen aid for the US government, but Trump claimed its spending was "inefficient" and his administration was pursuing direct bilateral deals to enhance openness and responsibility.
Based on statements, 16 African countries have to date agreed to similar health pacts, constituting over $18.3bn in committed funds.
Details of the Rejected Deal
This assistance for Zimbabwe would have funded "tackling HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We believe this partnership could have provided immense benefits for the people of Zimbabwe, particularly the 1.2 million men, women and children currently on HIV treatment through American-funded programmes," the Ambassador added.
However, official spokesman Nick Mangwana said the proposed deal was "unfair".
"Our nation was requested to provide its genetic material and health information over an extended period, with no corresponding promise of benefiting from any medical innovations – such as new medicines or tests – that could result from that provided information," Mangwana explained.
"In essence, our country would provide the raw materials for medical research with no assurance that the resulting innovations would be available to our people if a new health crisis arise."
Sovereignty and Global Health
He also said that the American exit from the World Health Organization (WHO) and its pursuit of bilateral health agreements were disrupting frameworks previously established through the international health agency.
Mangwana cited its Pandemic Benefit-Sharing system created to manage future global health emergencies.
"This mechanism is intended to guarantee that when a nation contributes its information, the benefits – including vaccines and treatments – are shared equitably, not monopolised exclusively by those with the capability to develop them."
The government's concerns over the US deal "are not meant as anti-American sentiment," Mangwana stressed.
"We welcome continued dialogue with our US partners on how subsequent co-operation could be designed in a way that respects the sovereignty and dignity of both nations."
Health Experts Response
Medical experts said it understood the official position, but recommended that talks should continue since a large portion of the country's Aids initiatives were funded by international support.
"If technical issues exist, such as those involving information security or implementation frameworks, these can often be resolved via detailed discussion and negotiated safeguards," it commented.
This impasse emphasises the ongoing debate between receiving vital international aid and safeguarding local interests in an increasingly interconnected world.